Christopher Marai analyst

Currently out of the existing stock ratings of Christopher Marai, 125 are a BUY (83.89%), 9 are a HOLD (6.04%), 15 are a SELL (10.07%).

Christopher Marai

Work Performance Price Targets & Ratings Chart

Analyst Christopher Marai works with a stock forecast success ratio of 57.94% fulfilled within 383.92 days on average. Previously, Christopher Marai worked at NOMURA, OPPENHEIMER.

Christopher Marai’s has documented 293 price targets and ratings displayed on 24 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRBP, Corbus Pharmaceuticals at 04-Jun-2020.

Wall Street Analyst Christopher Marai

Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 6/20/2016. The price target of $60 was fulfilled within 94 days with a profit of $42.15 (236.13%) receiving and performance score of 25.12.

Average potential price target upside

ALNY Alnylam Pharmaceuticals ALXN Alexion Pharmaceuticals BIIB Biogen BMRN Biomarin Pharmaceutical INCY yte PTCT PTC Therapeutics SRPT Sarepta Therapeutics XNCR Xencor FPRX Five Prime Therapeutics QURE Uniqure NV CLLS Cellectis SA GBT Global Blood Therapeutics GLPG Galapagos NV ADR PRTA Prothena plc PTGX Protagonist Therapeutics SLDB Solid Biosciences LLC SNDX Syndax Pharmaceuticals ARGX argenx NV ADR CRBP Corbus Pharmaceuticals DCPH Deciphera Pharmaceuticals LLC IMGN ImmunoGen MGNX MacroGenics MITO Stealth BioTherapeutics Corp VYGR Voyager Therapeutics

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

234

$79.61 (51.56%)

234

1 days ago

0/3 (0%)

$79.61 (51.56%)

Buy

235

$80.61 (52.21%)

235

1 months 8 days ago

2/14 (14.29%)

$85.31 (56.99%)

149

Buy

227

$72.61 (47.03%)

237

1 months 12 days ago

14/22 (63.64%)

$80 (54.42%)

171

Hold

161

$6.61 (4.28%)

171

1 months 12 days ago

2/2 (100%)

$14 (9.52%)

5

Buy

225

$70.61 (45.73%)

250

1 months 12 days ago

2/6 (33.33%)

$78 (53.06%)

435

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Christopher Marai?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?